WO2008127456A3 - Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use - Google Patents

Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use Download PDF

Info

Publication number
WO2008127456A3
WO2008127456A3 PCT/US2007/086642 US2007086642W WO2008127456A3 WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3 US 2007086642 W US2007086642 W US 2007086642W WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3
Authority
WO
WIPO (PCT)
Prior art keywords
anesthetics
methods
attenuating
toxins
drugs
Prior art date
Application number
PCT/US2007/086642
Other languages
French (fr)
Other versions
WO2008127456A2 (en
Inventor
David M Anderson
Vincent M Conklin
Benjamin C Cameransi
Original Assignee
Lyotropic Therapeutics Inc
David M Anderson
Vincent M Conklin
Benjamin C Cameransi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Therapeutics Inc, David M Anderson, Vincent M Conklin, Benjamin C Cameransi filed Critical Lyotropic Therapeutics Inc
Priority to EP07873662A priority Critical patent/EP2107904A4/en
Priority to JP2009540476A priority patent/JP2010512341A/en
Priority to AU2007351338A priority patent/AU2007351338B2/en
Priority to CA2672024A priority patent/CA2672024C/en
Publication of WO2008127456A2 publication Critical patent/WO2008127456A2/en
Publication of WO2008127456A3 publication Critical patent/WO2008127456A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Abstract

Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.
PCT/US2007/086642 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use WO2008127456A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07873662A EP2107904A4 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
JP2009540476A JP2010512341A (en) 2006-12-07 2007-12-06 Compositions for reversal and detoxification of anesthetics and other compounds and methods of use thereof
AU2007351338A AU2007351338B2 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
CA2672024A CA2672024C (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86895006P 2006-12-07 2006-12-07
US60/868,950 2006-12-07

Publications (2)

Publication Number Publication Date
WO2008127456A2 WO2008127456A2 (en) 2008-10-23
WO2008127456A3 true WO2008127456A3 (en) 2008-12-11

Family

ID=39864561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086642 WO2008127456A2 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Country Status (5)

Country Link
EP (1) EP2107904A4 (en)
JP (1) JP2010512341A (en)
AU (1) AU2007351338B2 (en)
CA (1) CA2672024C (en)
WO (1) WO2008127456A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871821C (en) * 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
JP6255975B2 (en) * 2012-12-27 2018-01-10 Jnc株式会社 Liquid crystal composition, antioxidant and liquid crystal display element

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922317A (en) * 1996-01-04 1999-07-13 The United States Of America As Represented By The Secretary Of The Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
WO2001022960A1 (en) * 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
US20030133877A1 (en) * 1997-07-21 2003-07-17 Levin Bruce H. Apparatus for directed intranasal administration of a composition
US20040143021A1 (en) * 2003-01-21 2004-07-22 Larijani Ghassem E. Compositions and methods for improving recovery after general anesthesia
WO2005034872A2 (en) * 2003-10-08 2005-04-21 Lyotropic Therapeutics, Inc. Drug-delivery vehicles based on reversed liquid crystalline phase materials
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012640A1 (en) * 1997-09-09 1999-03-18 Select Release, L.C. Coated particles, methods of making and using
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
CA2488705A1 (en) * 2002-06-13 2003-12-24 Lyotropic Therapeutics, Inc. A nanoporous particle with a retained target

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922317A (en) * 1996-01-04 1999-07-13 The United States Of America As Represented By The Secretary Of The Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
US20030133877A1 (en) * 1997-07-21 2003-07-17 Levin Bruce H. Apparatus for directed intranasal administration of a composition
WO2001022960A1 (en) * 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
US20040143021A1 (en) * 2003-01-21 2004-07-22 Larijani Ghassem E. Compositions and methods for improving recovery after general anesthesia
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005034872A2 (en) * 2003-10-08 2005-04-21 Lyotropic Therapeutics, Inc. Drug-delivery vehicles based on reversed liquid crystalline phase materials
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2107904A4 *

Also Published As

Publication number Publication date
JP2010512341A (en) 2010-04-22
EP2107904A2 (en) 2009-10-14
AU2007351338B2 (en) 2013-04-04
CA2672024C (en) 2014-07-08
EP2107904A4 (en) 2010-06-02
AU2007351338A1 (en) 2008-10-23
WO2008127456A2 (en) 2008-10-23
CA2672024A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
BRPI0906181A2 (en) "method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment "
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
ECSP13012618A (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
EA200701195A1 (en) CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
AR070834A1 (en) DOSAGE AND FORMULATION OF ACLIDINIO FOR THE TREATMENT OF RESPIRATORY DISORDERS
WO2007100675A3 (en) Collagenase for treating cellulite
WO2009043987A9 (en) Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2010129962A3 (en) Combination treatment of hydroxypyridonate actinide/lanthanide decorporation agents
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2015035410A8 (en) Cancer therapy
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
GB2456475A (en) Composition for the treatment of skin conditions
WO2008127456A3 (en) Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
CO6220945A2 (en) USE OF A COMPOSITION THAT INCLUDES FORMOTEROL AND DIPROPIANATE OF BECLOMETASONE FOR THE PREVENTION AND / OR TREATMENT OF AN EXAMERATION OF ASTHMA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873662

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007351338

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009540476

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2672024

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007351338

Country of ref document: AU

Date of ref document: 20071206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007873662

Country of ref document: EP